SynthesisAfrican health sciences2022

Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Xue Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.